The European Medicines Agency said it would look into anti-obesity medicines that contain orlistat, including Roche's Xenical and GlaxoSmithKline's Alli. Its move follows some rare cases of severe liver injury that could affect the drugs' benefit-risk profile. The EMA, the European Union's drug regulator, said the review would include the prescription-only medicine Xenical (orlistat 120 mg), and the lower dose over-the-counter-medicine Alli, as well as other medicines containing orlistat.
